Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06430866
Status:
RECRUITING
Last Update Posted:
2024-05-28
First Post:
2024-03-15
Brief Title:
Pharmacokinetic Similarity Between ABP 234 and Keytruda Pembrolizumab
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Randomized Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda Pembrolizumab in Participants With Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Eucalyptus
Brief Summary:
The primary objective of this study is to demonstrate pharmacokinetic PK similarity ABP 234 with pembrolizumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None